Journals / Turkish Journal of Hematology / 2000 / Cilt: 17 - Sayı: 3

Ticlopidine induced anemia and agranulocytosis

Pages
129–132
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The recovery of the granulocyte count and an improvement of the clinical condition were noted on the 6th day of the admission.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 63-year-old man with a history of transient ischemic attack had been treated with ticlopidine for 2 months.
📊
Key Findings & Data:He presented with a 6-day history of fever, sore throat, and generalized weakness.
💡
Conclusion & Impact:The recovery of the granulocyte count and an improvement of the clinical condition were noted on the 6th day of the admission.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Yaşlı · Agranülositoz · Erkek

Özet

A 63-year-old man with a history of transient ischemic attack had been treated with ticlopidine for 2 months. He presented with a 6-day history of fever, sore throat, and generalized weakness. Agranulocytosis and anemia due to ticlopidine was diagnosed, and the ticlopidine was discontinued. Broad-spectrum antibiotics and granulocyte colony stimulating factor were administered. The recovery of the granulocyte count and an improvement of the clinical condition were noted on the 6th day of the admission.

🔖

Cite This Article

KESKİN, A., SERMEZ, Y. (2000). Ticlopidine induced anemia and agranulocytosis. Turkish Journal of Hematology, Cilt: 17 - Sayı: 3, 129–132. https://ajindex.com/articles/413454

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Haynes RB, Sandler RS, Larson EB, Pater JL, Yatsu FM. A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Arch Intern Med 1992;152:1376-80
  2. Guerciolini R, Giordana G, Aversa F, Del Favero A. Anemia and agranulocytyosis associated with ticlopidine therapy. Acta Haemat 1985;73:232-4
  3. Szto GY, Linnemeier TJ, Ball MW. Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. Am J Cardiol 1999;83:138-9
  4. Carlson JA, Maesner JE. Fatal neutropenia and thrombocytopenia associated with ticlopidine. Ann Pharmacother 1994;28:1236-8
  5. Gur H, Wartenfeld R, Tanne D, Solomon F, Sidi Y. Ticlopidine-induced severe neutropenia. Postgrad Med J 1998;74:126-7
  6. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998;129:394-405
  7. Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. N Engl J Med 1989;321:501-7
  8. Harbison JW. Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study. Stroke 1992;23:1723-7
  9. Kao TW, Hung CC, Chen YC, Tien HF. Ticlopidineinduced aplastic anemia: Report of three Chinese patients and review of the literature. Acta Haematol 1997;98:211-3
  10. Mallet L, Mallet J. Ticlopidine and fatal aplastic anemia in an elderly woman. Ann Pharmacother 1994; 28:1169-71
  11. Mataix R, Ojeda E, Carmen Perez M, Jimenez S. Ticlopidine and severe aplastic anaemia. Br J Haematol 1992;80:125-6
  12. Gabrilove J. The development of granulocyte colony stimulating factor in its various clinical applications. Blood 1992;80:1382-5
  13. Spiekermann K, Roesler J, Emmendoerffer A, Elsner J, Welte K. Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications. Leukemia 1997; 11:466-78
  14. Korkmaz ME, Cekin AH. Bone marrow suppression and klebsiella pneumonia septicemia due to ticlopidine and successful treatment with filgrastim; a case report. Int J Cardiol 1998;66:317-8
  15. Nguyen BH, Parker RB, Geraci SA. Use of filgrastim for ticlopidine induced neutropenia following coronary stenting. J Invas Cardiol 1998;10:226-8
  16. Ruiz-Irastorza G, Alonso JJ, Iglesias JJ, Aguirre C. Granulocyte colony-stimulating factor for neutropenia secondary to